

OCT 15 2001

Corres. and Mail

RECEIVED

OCT 17 2001

45D-1750 (81841.0041)



BOX AF

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

R. J. Obremski, et al.

Serial No: 09/063,978

Filed: April 21, 1998

For: DETECTION OF VERY LOW QUANTITIES OF
ANALYTE BOUND TO A SOLID PHASE

Art Unit: 1645

Examiner: J. Hines

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: BOX AF, Commissioner for Patents Washington D.C. 20231, on October 12, 2001

Date of Deposit

Wei-Ning Yang, Reg. No. 38,690

Name

Signature

10/12/01

Date

BOX AF

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☒ Change of Correspondence Address is enclosed.
☒ No additional fee is required.

The fee has been calculated as shown below:

| | (Col. 1) CLAIMS REMAINING AFTER AMENDMENT | | (Col. 2) HIGHEST NUMBER PREVIOUSLY PAID FOR | (Col. 3) PRESENT EXTRA* | LG/SM \$ ENTITY FEE | | ADD'L FEE DUE |
|---|---|---|---|-------------------------------|--|----|------------------|
| TOTAL CLAIMS FEE | 28 | - | 28** | 0 | LG=\$18 SM=\$9 | \$ | \$ |
| INDEPENDENT CLAIMS FEE | 3 | - | 3*** | 0 | LG=\$80 SM=\$40 | \$ | \$ 0 |
| FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS | | | | | LARGE ENTITY FEE = \$270 SMALL ENTITY FEE = \$135 | | \$ |
| TOTAL | | | | | | | \$ |

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

- ☐ A check in the amount of \$___ to cover the additional claims fee is enclosed. **A copy of this sheet is enclosed.**
- ☐ A check in the amount of \$___ to cover the extension fee is enclosed. **A copy of this sheet is enclosed.**
- ☒ The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. **A copy of this sheet is enclosed.**
- ☒ Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted,
HOGAN & HARTSON L.L.P.By: 

Wei-Ning Yang

Registration No. 38,690

Attorney for Applicant(s)

Date: October 12, 2001

Biltmore Tower
500 South Grand Avenue, Suite 1900
Telephone: 213 337-6700
Facsimile: 213 337-6701

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

AFTER FINAL RESPONSE UNDER 37 C.F.R. §1.116
EXPEDITED PROCEDURE



PATENT
45D-1750
(81841.0041)

H (NE)
22
Linda
10/23/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

R. J. Obremski, *et al.*

Serial No: 09/063,978

Filed: April 21, 1998

For: DETECTION OF VERY LOW
QUANTITIES OF ANALYTE
BOUND TO A SOLID PHASE

Art Unit: 1645

Examiner: J. Hines

I hereby certify that this
correspondence is being deposited
with the United States Postal Service
with sufficient postage as first class
mail in an envelope addressed to:

Commissioner for Patents,
Washington D.C. 20231, on

October 12, 2001

Date of Deposit

Wei-Ning Yang, Reg. No. 38,690

Name

Signature

10/12/01

Date

RESPONSE UNDER
37 C.F.R. § 1.116

BOX AF

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the final Office Action dated August 14, 2001, favorable reconsideration is requested in view of the following remarks.

REMARKS:

Claims 1-28 are pending in the application and have been rejected. Claims 1-28 are presented for further prosecution. Favorable reconsideration of the application is requested in light of the remarks that follow.

The rejection of claims 1-4, 13-19, 21, and 23-26 under 35 U.S.C. § 103(a) as being unpatentable over Ekins *et al.*, EP 304,202 (the '202 patent), in view of Ekins *et al.*, J. of Clinical Immunoassay (Immunoassay reference), is maintained. Claims 27 and 28 are also rejected under 35 U.S.C. § 103(a) as being unpatentable over the same references. These rejections are respectfully traversed.